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Ten-eleven translocation (TET) proteins are recently characterized dioxygenases that regulate 
demethylation by oxidizing 5-methylcytosine to 5-hydroxymethylcytosine and further derivatives. 
The recent finding that 5hmC is also a stable and independent epigenetic modification indicates 
that these proteins play an important role in diverse physiological and pathological processes 
such as neural and tumor development. Both the genomic distribution of (hydroxy)methylation 
and the expression and activity of TET proteins are dysregulated in a wide range of cancers 
including prostate cancer. Up to now it is still unknown how changes in TET and 5(h)mC profiles 
are related to the pathogenesis of prostate cancer. In this review, we explore recent advances in 
the current understanding of how TET expression and function are regulated in development 
and cancer. Furthermore, we look at the impact on 5hmC in prostate cancer and the potential 
underlying mechanisms. Finally, we tried to summarize the latest techniques for detecting and 
quantifying global and locus-specific 5hmC levels of genomic DNA. 
 
1 Introduction 
Recent large-scale genome sequencing studies have classified primary prostate cancer (PCa) 
into distinct molecular subtypes, defined by specific genetic alterations (Cancer Genome Atlas 
Research, 2015).  Gene-fusions involving the ETS family of transcription factors occur in over 
50% of primary prostate cancers, with the next most common subtype defined by mutations in 
the SPOP gene (~10% cases) (Cancer Genome Atlas Research, 2015). In addition to these 
genetic alterations there are recurrent epigenetic changes that occur in over 80% cases and that 
show less intra-tumor heterogeneity compared to genetic changes (Bastian, Yegnasubramanian, 
Palapattu et al., 2004,Cooper, Eeles, Wedge et al., 2015,Massie, Spiteri, Ross-Adams et al., 
2015), suggesting that these are early and recurrent events. In addition there are also epigenetic 
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changes that vary between tumor foci and change progressively from early to late stage disease 
(Brocks, Assenov, Minner et al., 2014,Yegnasubramanian, Haffner, Zhang et al., 2008), 
highlighting the ongoing epigenetic evolution in prostate tumors. 
The epigenetic changes observed in prostate tumors may be shaped by extrinsic factors (e.g. 
metabolic stress (Sciacovelli, Goncalves, Johnson et al., 2016,Thienpont, Steinbacher, Zhao et 
al., 2016)) and cell-intrinsic factors (e.g. genetic alterations impinging on epigenetic regulators 
(Cancer Genome Atlas Research, 2015,Spans, Van den Broeck, Smeets et al., 2016)). For 
example, a rare molecular subtype of prostate cancer is defined by recurrent point mutations in 
the IDH1 gene, resulting in increased production of the oncometabolite 2-hydroxyglutarate (2-
HG) that inhibits several 2-oxoglutarate (2-OG) dependent deoxygenases including enzymes 
involved in the metabolism of DNA methylation. 
In mammalian cells, DNA methylation occurs on the 5’ position of cytosine bases, predominantly 
at CpG dinucleotides, and is mediated by DNA methyltransferases (DNMT1, DNMT3a/b) using 
S-adenosylmethionine (SAM) as a methyl-donor (Chiang, Gordon, Tal et al., 1996,Gold, Hurwitz 
and Anders, 1963). Cytosine methylation (5mC) at transcriptional regulatory elements is 
associated with reduced gene expression and tissue-specific 5mC profiles are implicated in 
canalization of cellular differentiation (Razin and Riggs, 1980,Roadmap Epigenomics, Kundaje, 
Meuleman et al., 2015). 5mC oxidation results in 5-hydroxymethylcytosine (5hmC), a base that 
was first identified as a constituent of bacteriophage DNA in 1952 (Wyatt and Cohen, 1952) and 
was subsequently found in mammalian tissues in 1972 (Penn, Suwalski, O'Riley et al., 1972). It 
was not until 2009 when the ten-eleven translocation methylcytosine dioxygenase (TET) family 
of proteins were implicated in the oxidation of 5mC to 5hmC that interest in this base began to 
grow (Tahiliani, Koh, Shen et al., 2009). Initial excitement over 5hmC was due to the implication 
of this modification in the active demethylation of 5mC during epigenetic reprogramming (He, Li, 
Li et al., 2011,Ito, Shen, Dai et al., 2011), however much recent attention has focused on 5hmC 
as a stable epigenetic mark involved in transcriptional regulation and lineage specification 
(Bachman, Uribe-Lewis, Yang et al., 2014,Koh, Yabuuchi, Rao et al., 2011,Zhang, Su, Jeong et 
al., 2016).  
The functional impact of 5hmC therefore appears to be context-dependent and locus-specific.  In 
this review we explore the mechanisms regulating the expression and function of the TET family 
and the impact on 5hmC in development and cancer, before focusing on a specific summary of 
TET and 5hmC alterations in prostate cancer and the mechanisms underlying these changes.    
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2 The TET gene family 
The ten-eleven translocation family of proteins (TET1-3) was initially identified because of the 
involvement of TET1 as a fusion partner of the histone methyltransferase (MLL) gene in acute 
myeloid leukemia (Lorsbach, Moore, Mathew et al., 2003,Ono, Taki, Taketani et al., 2002). The 
TET protein family members are mammalian homologs of the trypanosome base J binding 
proteins JBP1 and JBP2, which were found to oxidize the 5-methyl group of thymine (Iyer, 
Tahiliani, Rao et al., 2009,Tahiliani et al., 2009). Although 5-hydroxymethylcytosine (5hmC) had 
previously been detected in mammalian genomes, the functional importance of this modification 
was not further investigated until Tahiliani and colleagues discovered that TET proteins are 
dioxygenases that participate in the DNA demethylation pathway by oxidizing 5-methylcytosine 
(5mC) to 5-hydroxymethylcytosine (Tahiliani et al., 2009). 5hmC is a substrate for deamination 
into 5-hydroxymethyluridine (5hmU) by activation-induced deaminase (AID) and apolipoprotein B 
mRNA-editing enzyme complex (APOBEC), followed by base excision repair (BER) (Guo, Su, 
Zhong et al., 2011). It can also be converted to 5-formylcytosine (5fC) and finally to 5-
carboxylcytosine (5caC) with subsequent base-excision repair to yield unmethylated cytosines 
(He et al., 2011,Ito et al., 2011). Decarboxylation of 5caC by unknown enzymes or removal of 
the base by thymine DNA glycosylase or other DNA repair enzymes further completes the 
demethylation pathway (He et al., 2011,Ito et al., 2011,Tahiliani et al., 2009). For these 
reactions, TET enzymes require 2-oxoglutarate (2-OG or α-ketoglutarate) and Fe(II) as 
cofactors, rendering their activity acutely dependent on central metabolism and oxygen levels. 
The TET family members (TET1-3) all have the same catalytic activity but vary in structural 
domains (Figure 1). TET proteins harbor a core catalytic oxygenase domain with a double-
stranded β-helix (DSβH) containing metal-binding residues which are characteristic for 2-OG 
and Fe(II)-dependent oxidation (Loenarz and Schofield, 2011). This core domain is typically 
preceded by a cysteine-rich domain that seems to be required for enzymatic activity (Iyer et al., 
2009,Tahiliani et al., 2009). TET proteins catalyze demethylation by binding Fe(II) through 
conserved His-His-Asp residues. This generates a reactive enzyme-bound Fe(IV)-oxo 
intermediate by using molecular oxygen from 2-OG, which reacts with 5mC to yield 5hmC. 
At their N-terminus, TET1 and TET3 contain a CXXC zinc finger domain, a motif that is also 
found in DNMT1 and is required for direct DNA-binding of DNMT1 (Pradhan, Esteve, Chin et al., 
2008,Xu, Wu, Tan et al., 2011,Zhang, Zhang, Clark et al., 2010). This domain has been reported 
to recognize unmodified, methylated and hydroxymethylated cytosines and binds preferentially 
to genomic regions with high CpG content (Pradhan et al., 2008,Risner, Kuntimaddi, Lokken et 
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al., 2013,Xu et al., 2011,Zhang et al., 2010). TET2 does not contain a CXXC-domain but 
associates with the IDAX protein which contains a CXXC-domain (Ko, An, Bandukwala et al., 
2013). Divergent sequence specificity has been reported for CXXC-domain containing proteins 
(Frauer, Rottach, Meilinger et al., 2011,Risner et al., 2013), and TET deletion mutants lacking 
CXXC-domains seem to retain activity to hydroxylate genomic 5mC (Frauer et al., 2011,Liu, 
Wang, Deng et al., 2013). Together, these data suggest that the recruitment of TET enzymes to 
specific genomic loci may occur through direct CXXC-domain DNA binding and also indirectly as 
part of protein-complexes (Nakagawa, Lv, Nakagawa et al., 2015,Yildirim, Li, Hung et al., 2011). 
The exact combination of direct binding and protein-interaction partners may in part contribute to 
the differential recruitment of TET proteins in particular cellular contexts.  
 
 
 
Figure 1: Schematic representation of mutations in TET family in PCa. TET1-3 missense, nonsense 
substitutions and insertions/deletions are represented in a simplified protein structure showing the DNA 
binding domain (DBD) and catalytic domain (CD). The dots represent how frequent the mutations occur in 
different samples. The scheme contains both primary PCa samples and metastatic samples (indicated 
with an arrow). This representation is based on data retrieved from cBioPortal (http://www.cbioportal.org/), 
COSMIC (http://cancer.sanger.ac.uk/cosmic) and (Spans et al., 2016). One sample has been excluded for 
its hyper mutated genotype (TCGA-XK-AAIW; 6517 nonsynonymous mutations among which 4 mutations 
are located within TET genes). 
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3 5hmC and the TET enzymes 
3.1 Role in transcriptional regulation 
One of the best studied covalent DNA modifications is 5mC, which is most prevalent in CpG 
islands (70-80% of CpGs are methylated). The accumulation of 5mC at gene promoters and 
enhancers is associated with gene repression (Lee, Morton, Epstein et al., 1994,Nelson, Lee, 
Nguyen et al., 1997). DNA demethylation occurs in different biological contexts. Passive 
demethylation refers to the loss of 5mC in a replication-dependent manner during cell division. A 
process for active demethylation was predicted from studies in early development (Mayer, 
Niveleau, Walter et al., 2000,Santos, Hendrich, Reik et al., 2002), but this demethylation process 
remained unknown for decades. The characterization of TET, thymine-DNA glycosylase (TDG) 
and AID/APOBEC activity defined a pathway for 5mC demethylation (Guo, Li, Liang et al., 
2014,He et al., 2011,Morgan, Dean, Coker et al., 2004,Tahiliani et al., 2009), and at least 
initially, 5hmC was considered as an intermediate of the demethylation pathway (Ito, D'Alessio, 
Taranova et al., 2010,Williams, Christensen and Helin, 2011). Recent studies have confirmed 
that in addition to 5hmC being an intermediate step in demethylation, that 5hmC is a stable DNA 
modification that is present at higher levels in tissues with low replication rates (Bachman et al., 
2014), and that conversely 5hmC is decreased in rapidly proliferating tissues and in cancer (Jin, 
Jiang, Qiu et al., 2011,Lian, Xu, Ceol et al., 2012). Not only are TET proteins involved in the 
demethylation pathway, but they have also been shown to physically bind to DNA to prevent 
DNA methylation on specific loci (Wu and Zhang, 2011). Recent publication suggests that TET 
proteins are not only able to hydroxymethylate DNA, but also RNA (Delatte, Wang, Ngoc et al., 
2016). Therefore, it is believed that TET enzymes have a direct influence on gene transcription.  
Indeed, TET1 DNA binding and associated 5hmC markers are found in 5’ gene regulatory 
regions and are associated with active gene transcription (Stroud, Feng, Morey Kinney et al., 
2011,Williams, Christensen, Pedersen et al., 2011,Wu and Zhang, 2011). Recent studies have 
shown that 5hmC regulates gene transcription at least in part by directing the dynamic 
organization and remodeling of chromatin structures. For example, 5hmC can inhibit the binding 
of the methyl-CpG binding domain of MeCP2, MBDs and RING/zinc-finger domain-containing 
proteins to DNA (Jin, Kadam and Pfeifer, 2010,Valinluck, Tsai, Rogstad et al., 2004). These 
chromatin readers repress transcription at loci marked with DNA methylation and therefore, it is 
suggested that the 5hmC marks can counteract 5mC-mediated transcriptional repression (Tan 
and Shi, 2012).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
An example of the transcriptional activating role of the TET proteins is the enrichment of TET1 
and 5hmC at regulatory regions of pluripotency factors such as Nanog in mouse embryonic stem 
cells (mESC) (Ito et al., 2010). Knockdown of Tet1 or Tet2 in this system is associated with 
lowered expression levels of these factors by promoter hypermethylation (Ficz, Branco, 
Seisenberger et al., 2011,Ito et al., 2010). In addition, a transcriptionally repressive role for TET 
proteins has been proposed at Polycomb target gene promoters where TET1 contributes to 
repressive chromatin complexes in ESCs (Williams et al., 2011,Wu, D'Alessio, Ito et al., 2011).   
Based on these findings, 5hmC can be considered as a stable epigenetic marker in its own right, 
in addition to being an intermediate of the demethylation pathway. Clearly, the emerging 
transcriptional activating and repressing roles of the TET proteins at key genomic loci imply that 
they play an important function in normal development, pluripotency and tumor suppression. 
3.2 Role in development 
During the early stages of development there is a role for TET proteins in epigenetic 
reprogramming. Immediately after fertilization, while the paternal and maternal pronuclei move 
towards each other, maternal TET3 catalyzes demethylation in the paternal pronucleus (Gu, 
Guo, Yang et al., 2011,Iqbal, Jin, Pfeifer et al., 2011,Wossidlo, Nakamura, Lepikhov et al., 2011) 
and a partial demethylation in the maternal pronucleus (Guo et al., 2014). Even in primordial 
germ cells (PGCs), which migrate into the gonad region at embryonic day 7 and develop into 
oocytes and sperm cells, genome-wide demethylation as well as chromatin remodeling is 
observed (Hajkova, Ancelin, Waldmann et al., 2008). This demethylation step is carried out 
through a replication-dependent mechanism initiated by TET1 and TET2 (Hackett, Sengupta, 
Zylicz et al., 2013). Expression patterns of TET enzymes suggest functional specificity: Tet1 and 
Tet2 are expressed in PGCs, whereas Tet3 is highly expressed in oocytes (Gu et al., 
2011,Hajkova, 2010,Surani and Hajkova, 2010). However, normal development of PGCs is not 
ablated by the knockout of individual Tet genes (Dawlaty, Ganz, Powell et al., 2011,Gu et al., 
2011,Ko, Bandukwala, An et al., 2011), suggesting a level of functional redundancy at least 
between Tet1 and Tet2. 
TET1 also plays an essential role in regulating pluripotency and differentiation in mouse 
embryonic stem cells (ESCs). Both TET1 and TET2 are abundantly expressed in mESCs, 
accompanied by high 5hmC levels (Ito et al., 2010,Koh et al., 2011,Ruzov, Tsenkina, Serio et 
al., 2011). It was recently shown that TET1 can functionally replace transcription factors such as 
OCT4 and SOX2 during somatic cell reprogramming to successfully generate induced 
pluripotent stem cells (Chen, Gao, Huang et al., 2015,Gao, Chen, Li et al., 2013). Both Tet1 and 
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Tet2 are rapidly downregulated upon differentiation (Ito et al., 2010,Koh et al., 2011,Tahiliani et 
al., 2009), whereas Tet3 levels rise. Further illustration of selectivity of TET activities came from 
Ito and colleagues who reported that KO of Tet1 induced spontaneous differentiation of mESCs 
into trophoblasts in vitro, whereas this was not the case for KO of other Tet family members 
(Dawlaty et al., 2011,Ito et al., 2010). Tet1 KO in mESCs showed 35% reduction in 5hmC levels 
and subtle changes in gene expression (Dawlaty et al., 2011). Surprisingly, the homozygous KO 
of Tet1 or Tet2 did not seem to affect normal development in mice (Dawlaty et al., 2011,Li, Cai, 
Cai et al., 2011,Moran-Crusio, Reavie, Shih et al., 2011,Quivoron, Couronne, Della Valle et al., 
2011). No difference in gene expression was found in Tet3 KO compared to wild type controls 
(Shen, Inoue, He et al., 2014), suggesting compensation from other TET family members. Most 
double Tet1/Tet2 deficient mice survive to adulthood, but some die late in embryogenesis or 
shortly after birth (Dawlaty, Breiling, Le et al., 2013). In contrast, knockout of Tet3 led to neonatal 
lethality (Guo et al., 2011), and Tet1-3 triple deficient mESCs show major defects in 
differentiation and reprogramming (Dawlaty, Breiling, Le et al., 2014,Hu, Zhang, Mao et al., 
2014). This stresses the important involvement of TET3 during embryogenesis and illustrates 
the partial redundancy between TET proteins. 
Postnatally, levels of 5hmC are very tissue- and locus dependent. The highest 5hmC levels have 
been found in the central nervous system (CNS) (Globisch, Munzel, Muller et al., 
2010,Szwagierczak, Bultmann, Schmidt et al., 2010). Hydroxymethylation levels in the 
cerebellum and hippocampus are higher in adult mice compared to newborns (Szulwach, Li, Li 
et al., 2011). In general, 5hmC is even higher in terminally differentiated cells than in progenitor 
cells in the CNS (Haffner, Chaux, Meeker et al., 2011,Haffner, Pellakuru, Ghosh et al., 2013,Orr, 
Haffner, Nelson et al., 2012). In these cells, the local levels of 5hmC were found to be inversely 
correlated with MECP2 binding at regions with differential 5-hydroxymethylation (Szulwach et al., 
2011).   
As previously mentioned, Tet1 and Tet2 KO mice are viable and fertile (Dawlaty et al., 2011,Li et 
al., 2011,Moran-Crusio et al., 2011), and Tet3 KO leads to neonatal lethality (Gu et al., 2011). 
However, Tet1 KO mice do display reduced body mass and smaller litter size (Dawlaty et al., 
2011). More detailed analyses of Tet2 KO mice revealed that TET2 activity is critical for normal 
hematopoietic lineage differentiation (Madzo, Vasanthakumar and Godley, 2013,Madzo, Liu, 
Rodriguez et al., 2014). TET2 modulates the balance between self-renewal and differentiation in 
hematopoietic stem cells. Moreover, mutations in TET2 have been found in multiple types of 
leukemia (Ko, Huang, Jankowska et al., 2010,Li et al., 2011,Moran-Crusio et al., 2011,Quivoron 
et al., 2011), and knockout of Tet2 leads to hematopoietic phenotypes such as myelomonocytic 
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leukemia (Albano, Anelli, Zagaria et al., 2011,Chou, Chou, Liu et al., 2011,Ko et al., 2011,Li et 
al., 2011,Moran-Crusio et al., 2011,Quivoron et al., 2011,Weissmann, Alpermann, Grossmann et 
al., 2012). 
3.3 Role in malignancies 
The identification of the TET1 gene as a recurrent translocation partner in acute myeloid 
leukemia was a first hint to its role in the oncogenic process. Based on rodent models, ET1 can 
be considered a tumor suppressor of hematopoietic malignancy and more specifically B cell 
lymphoma (Cimmino, Dawlaty, Ndiaye-Lobry et al., 2015). TET2 mutations were found in up to 
30% of patients with myeloid malignancies such as chronic myelomonocytic leukemia, acute 
myeloid leukemia (AML) and myelodysplastic syndromes (Albano et al., 2011,Chou et al., 
2011,Ko et al., 2010,Madzo et al., 2013,Weissmann et al., 2012). TET2 mutations have also 
been reported in solid tumors including clear-cell renal cell carcinoma, prostate cancer (PCa), 
and breast cancer (Abdel-Wahab, Mullally, Hedvat et al., 2009,Chung, Schatoff and Abdel-
Wahab, 2012,Delhommeau, Dupont, Della Valle et al., 2009,Ko et al., 2010,Nickerson, Im, 
Misner et al., 2013,Sato, Yoshizato, Shiraishi et al., 2013,Takahashi, 2013,Wu and Ling, 2014). 
In myeloid malignancies, mutations in TET2 are mainly loss-of-function whereas in solid tumors 
missense mutations are clustered in the catalytic domain of the gene, suggesting that disruption 
of TET2 dioxygenase activity provides a selective advantage in multiple tumor types (Ko et al., 
2010). This notion is corroborated by the observation that TET2 mutations in AML are 
predominantly associated with genomic hypermethylation (Ko et al., 2010,Madzo et al., 2013). 
Recent studies have shown that the overall 5hmC level in genomic DNA is substantially 
decreased in many solid tumors, which has been linked to reduced expression levels of the TET 
family members (Jin et al., 2011,Kudo, Tateishi, Yamamoto et al., 2012,Lian et al., 2012,Yang, 
Liu, Bai et al., 2013). There is an inverse correlation between TET expression and robust tumor 
growth and metastasis in colorectal cancer (Gambichler, Sand and Skrygan, 2013,Hsu, Peng, 
Kang et al., 2012,Lian et al., 2012). Furthermore, lower TET levels are associated with poor 
prognosis of patients with early breast cancer and prostate cancer (Spans, Van den Broeck, 
Smeets et al., 2016,Yang, Yu, Hong et al., 2015). Studies in prostate cancer have reported 
reduced 5hmC levels in tumor versus normal tissue and suggested this as a potential biomarker 
for malignant transformation (Haffner et al., 2011,Yang et al., 2013). More recently, 5hmC levels 
were shown to be significantly reduced in ETS-related gene (ERG) negative PCa compared to 
normal prostate tissue samples, and this change has been proposed as a potential prognostic 
marker in ERG negative (but not in ERG positive) prostate cancers (Strand, Hoyer, Lynnerup et 
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al., 2015). These data are suggestive for a tumor suppressive role of TET proteins in prostate 
cancer. 
 
4 Regulation of TET genes 
4.1 Transcriptional control 
The TET enzymes are tightly regulated at many levels of gene expression. Here, most relevant 
pathways in prostate cancer will be discussed. Promoter studies revealed two alternative 
promoters for mouse Tet1 as well as Tet2, resulting in different isoforms (Neri, Incarnato, 
Krepelova et al., 2015,Sohni, Bartoccetti, Khoueiry et al., 2015,Zhang, Xia, Wang et al., 2016). 
The Tet1a isoform contains a CXXC DNA-binding domain and is regulated by ESC-cell specific 
transcription factors including SOX2 and KLF4, while the Tet1b isoform lacks the CXXC-domain 
and is transcribed from an alternative promotor in differentiated cells independently of 
pluripotency transcription factors (Neri et al., 2015,Sohni et al., 2015). In human cells only one 
TET1 isoform has been characterized, however the human TET1 gene includes an enhancer 
region that is bound by the pluripotency factors OCT4, SOX2 and NANOG (Neri et al., 2015). 
Other transcription factors known to regulate TET expression are the high-mobility group AT-
hook 2 (HMGA2) and hypoxia inducible factor (HIF)-1a (Song, Poliseno, Song et al., 2013,Sun, 
Song, Huang et al., 2013). Indeed, several groups reported that all three members of the TET 
family can be directly regulated by HIF-1a through binding in the proximal promoter region of 
TET genes (Mariani, Vasanthakumar, Madzo et al., 2014,Thienpont et al., 2016,Wu, Chen, Nieh 
et al., 2015). Furthermore, regulation can be controlled by epigenetic mechanisms such as 
hypermethylation of the TET promoter (Chim, Wan, Fung et al., 2010,Cimmino et al., 2015).  
4.2 Post-translational control 
The activity of TET enzymes is also tighly regulated at the protein level. Major influence on TET 
activity include central metabolism and oxygen availability. TET enzymes are oxygen-dependent 
dioxygenases and recently tumor hypoxia was shown to reduce TET activity and DNA 
demethylation (Thienpont et al., 2016). Furthermore, tricarboxylic acid (TCA) cycle intermediate 
metabolites have been implicated in TET regulation. Isocitrate dehydrogenase (IDH) proteins 
convert isocitrate to 2-OG using NADP+/NADPH as cofactors (Figure 2). Since 2-OG is an 
essential cofactor for dioxygenases such as TET proteins, IDH enzymes are important 
regulators of TET activity. Other rate-limiting steps up- and downstream of 2-OG in central 
metabolism also have the potential to influence TET activity, including oxygen levels, TCA cycle 
activity and anabolic processess that utilize TCA metabolites. Mutations in other enzymes 
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participating in the TCA cycle such as succinate dehydrogenase (SDH) and fumarate hydratase 
(FH) have been described in cancer too (Adam, Yang, Soga et al., 2014,Xiao, Yang, Xu et al., 
2012). Loss-of function mutations in these enzymes result in accumulation of succinate or 
fumarate respectively, impairing the activity of 2-OG-dependent dioxygenases such as TET, 
reducing DNA demethylation (Sciacovelli et al., 2016).  
 
 
 
Figure 2: Crosstalk between TET and key enzymes involved in metabolism and glycosylation. 
Several enzymes involved in the TCA cycle such as isocitrate dehydrogenase (IDH), succinate 
dehydrogenase (SDH) and fumarate hydratase (FH) have been reported to influence TET activity in 
cancer. 2-OG is a product of the TCA cycle and an essential co-factor of TET, thus mutations in IDH as 
well as glutamine deficiency affect its hydroxymethylating capacity. High levels of zinc inhibit aconitase 
(ACO) resulting in reduced flux through the TCA cycle. Glucose metabolism modulates the activity of OGT 
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which glycosylates serine and threonine residues of diverse proteins including TET. TET also enables 
GlcNAcylation by recruitment of OGT to the chromatin.   
 
 
O-Linked N-Acetylglucosamine (GlcNAc) Transferase (OGT) glycosylates hydroxyl groups of 
specific serine and threonine residues in many different nuclear and cytoplasmic proteins, 
thereby controlling their transcription, activity, stability and localization (Ozcan, Andrali and 
Cantrell, 2010). There is a direct interaction between phosphorylated TET proteins and OGT 
(Chen, Chen, Bian et al., 2013,Deplus, Delatte, Schwinn et al., 2013,Ito, Katsura, Shimada et al., 
2014,Zhang, Liu, Gao et al., 2014), and TET-OGT complexes mainly co-localize on H3K4me3 
positive, CpG-rich promoters at sites of active gene transcription (Chen et al., 2013,Deplus et al., 
2013,Vella, Scelfo, Jammula et al., 2013). This interaction results in the O-GlcNAc modification 
of TETs, thereby decreasing available phosphorylation sites and increasing protein stability and 
promoting DNA demethylation (Bauer, Gobel, Nagaraj et al., 2015,Shi, Kim, Lu et al., 2013,Vella 
et al., 2013). In addition, TET proteins are essential for efficient recruitment of OGT to chromatin 
in order to facilitate the modification of histones (Chen et al., 2013,Deplus et al., 2013,Vella et 
al., 2013). Increased glucose consumption also leads to a higher production of UDP-N-
acetylglucosamine (UDP-GlcNAc), which is further used by OGT to glycosylate various proteins. 
Dysregulation of OGT-TET interaction and co-localization might therefore affect the stability of 
TET itself, but also of many other target genes such as tumor suppressor genes and oncogenes 
(p53, c-Myc) (Itkonen, Minner, Guldvik et al., 2013,Yang, Kim, Nam et al., 2006). 
 
Additional post-translational modifications have been reported to influence TET activity including 
poly (ADP-ribosyl)ation (PARylation) which is catalyzed by enzymes of the poly(ADP-ribose) 
polymerase (PARP) family. PARPs use NAD+ as a substrate producing negatively charged 
polymers of ADP-ribose which are then hydrolyzed by the poly(ADP-ribose) glycohydrolase 
(PARG) (Schreiber, Dantzer, Ame et al., 2006). PARylation participates in highly diverse cellular 
processes such as DNA damage response, transcription and apoptosis (Beck, Robert, Reina-
San-Martin et al., 2014,Krishnakumar and Kraus, 2010,Schreiber et al., 2006). A direct protein-
protein interaction between TET1 and PARP1 has been reported associated with PARylation 
and enhanced TET1 activity (Ciccarone, Valentini, Zampieri et al., 2015). Recently, TET1 gene 
expression has also been found to be positively regulated by PARylation through 
hypomethylation of CpG islands in the TET promoter region (Ciccarone, Valentini, Bacalini et al., 
2014).  
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Lastly, an important nutritional factor has been implicated in TET regulation at the protein level. 
Vitamin C (or L-ascorbic acid) is an essential antioxidant in mammals which is required for 
collagen, catecholamine and carnitine biosynthesis (Banhegyi, Benedetti, Margittai et al., 
2014,Englard and Seifter, 1986). It is also an essential cofactor of Fe(II)- and 2-OG-dependent 
dioxygenases (such as TET enzymes), acting as an electron donor, adjusting the redox state of 
enzymes and reducing Fe(III) to Fe(II). In mouse ES-cells, vitamin C enhances TET activity and 
therefore promotes demethylation, leading to global increase of 5hmC levels (Blaschke, Ebata, 
Karimi et al., 2013). This activation is possibly mediated by a direct mechanism whereby vitamin 
C directly binds to the catalytic domain of TET (Yin, Mao, Zhao et al., 2013). 
 
5 5hmC landscapes in cancer 
Hydroxymethylation is inversely associated with cell proliferation as 5hmC levels are decreased 
in rapidly proliferating tissues and cancer (Jin et al., 2011,Lian et al., 2012). When staining 
different cancer types such as prostate cancer for 5hmC and proliferation marker Ki67, cells that 
lost 5hmC present with high levels of Ki67 (Jin et al., 2011). It is believed that 5hmC levels play 
an important role in gene regulation, but the genomic distribution of 5hmC marks in normal and 
cancer tissues is still largely unknown. 
A global decrease of 5hmC was first observed in hematological malignancies (Coutinho, Monte-
Mor, Vianna et al., 2015,Huang and Rao, 2014,Ko, An, Pastor et al., 2015) and later also in solid 
cancers including breast cancer, colon cancer, melanoma and prostate cancer (Haffner et al., 
2011,Lian et al., 2012,Murata, Baba, Ishimoto et al., 2015,Spans et al., 2016,Udali, Guarini, 
Moruzzi et al., 2015). In melanoma, hypo-5hmC was determined at the gene level for RAC3, 
IGF1R and TIMP2 (Lian et al., 2012). However, while the general trend in tumors is global 5hmC 
decrease, some cancers such as pancreatic cancer are characterized by increased 5hmC levels 
(Bhattacharyya, Yu, Suzuki et al., 2013,Huang, Jiang, Li et al., 2013,Navarro, Yin, Ono et al., 
2014). 
Technological improvements and detailed studies have revealed more complex landscapes 
where 5hmC patterns at individual genomic regions can differ considerably. While tissue and 
cellular studies have shown that 5hmC is globally decreased in cancer, high-resolution genome-
wide studies have shown local enrichment of 5hmC at promoters, enhancers and gene bodies of 
actively expressed genes (Stroud et al., 2011,Xu et al., 2011). A broad redistribution of 5hmC 
across the genome was detected in several cancers such as melanoma and pancreatic cancer 
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(Bhattacharyya et al., 2013,Lian et al., 2012,Thomson, Hunter, Lempiainen et al., 2013). This 
redistribution generally includes a decrease in 5hmC around transcriptional start sites (TSS) and 
increased levels in gene bodies, although the overall level is lower in cancer cells compared to 
normal cells.  
To date, few studies have studied 5hmC genome-wide in cancer tissues and further work is 
needed to map tissue-specific and cancer type-specific 5hmC in order to reveal the diversity of 
5hmC changes and to identify molecular signatures.   
 
6 TET and 5hmC in prostate cancer 
The clinical behavior of primary as well as metastatic prostate cancer is highly variable with 
substantial intra- and interpatient heterogeneity and differential outcome. Current risk 
stratifications of primary tumors combine clinical and pathological parameters including Gleason 
score, PSA and clinical staging (D'Amico, Whittington, Malkowicz et al., 1998). These risk 
stratifications may be refined by the inclusion of genetic and epigenetic profiling, such as point 
mutations (SPOP, TP53, PTEN, and FOXA1), copy-number alterations, gene fusions 
(TMPRSS2-ERG) and (hydroxy-)methylation landscapes (Barbieri, Baca, Lawrence et al., 
2012,Massie, Mills and Lynch, 2016,Taylor, Schultz, Hieronymus et al., 2010,Tomlins, Rhodes, 
Perner et al., 2005,Wang, Shankar, Dhanasekaran et al., 2011).  
The Cancer Genome Atlas (TCGA) Research Network recently proposed a new molecular 
taxonomy of primary prostate cancer based on data from 333 primary prostate tumors (Cancer 
Genome Atlas Research, 2015). They found that 74% of all prostate tumors can be subdivided 
in one of seven molecular classes, based on fusions involving ERG (46%), ETV1 (8%), ETV4 
(4%) or FLI1 (1%) and on mutations in SPOP (11%), FOXA1 (3%) or IDH1 (1%). All of these 
mutated genes either encode transcription factors or are related to gene expression and 
epigenetics. Within these different subclasses, epigenetic profiling revealed a diversity of 5mC 
changes that was not clearly separated by molecular subtypes but did correlate with gene 
silencing. In addition, approximately one in four prostate tumors could not be classified. Either 
these unclassified tumors belong to undiscovered subclasses, or there is missing information 
linking them to any of the existing classes.   
6.1 Genetic alterations of TET genes in prostate cancer 
Genetic alterations are infrequent events in prostate cancer. Mutations that have been found in 
localized prostate cancer for all three TET genes, showing a similar distribution (Figure 1). 
Strikingly, 70% of these identified mutations are located within the catalytic domain, possibly 
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having detrimental effects on TET enzymatic activity. Mutations in the TET genes were also 
detected in a large cohort of castration-resistant prostate cancer patients (Robinson, Van Allen, 
Wu et al., 2015). Again, most of the mutations detected in metastatic PCa are located within the 
catalytic domain (included in Figure 1). 
Spans and colleagues identified a high risk patient with a TET1 mutation in its catalytic domain 
showing distinct hydroxymethylation patterns (Spans et al., 2016). In this study, 15% of the high-
risk prostate cancer samples presented with a loss of at least one TET1 copy and 39 out of 40 
samples (97.5%) showed decreased TET1 levels, suggesting other mechanisms of TET1 
repression in prostate cancer. Further studies are needed to functionally characterize these 
mutations and the consequences of reduced TET1 expression in prostate cancer. If validated, 
we propose that these tumors could be added to the IDH1 molecular group of prostate cancers, 
since IDH1 mutants are also known to impair TET1 activity and tumors with IDH1 mutations 
present with altered 5mC profiles (Xu, Yang, Liu et al., 2011). 
6.2 TET transcription in prostate cancer 
The mechanisms of transcriptional regulation of the TET genes in prostate cancer are still largely 
unknown. However, many signals are expected to converge on the TET genes. The expression 
levels of the TET gene regulating transcription factors OCT4, SOX2 and MYC are frequently 
altered in prostate cancer (Amini, Fathi, Mobalegi et al., 2014,Gu, Yuan, Wills et al., 2007,Koh, 
Bieberich, Dang et al., 2010,Sotomayor, Godoy, Smith et al., 2009,Ugolkov, Eisengart, Luan et 
al., 2011,Yu, Cates, Morrissey et al., 2014), suggesting that there may commonly be alterations 
on the TET transcription levels. The transcriptional repressor HMGA2 is also selectively 
activated during prostate development and its overexpression in prostate cells promotes 
formation of prostate intraepithelial neoplasia (PIN) lesions in xenografts (Zong, Huang, 
Sankarasharma et al., 2012).  In breast cancer cell lines, it was shown that knockdown of 
HMGA2 induces TET1 expression which is protective against tumor growth and development of 
metastases (Sun et al., 2013). Thus, overexpression of HMGA2 in prostate cancer cells might 
also downregulate TET expression. 
TET expression levels are also controlled at the epigenetic level by the DNA-methyltransferases 
(DNMTs). DNMT1 acts mainly as a maintenance methyltransferase and DNMT3a/b 
predominantly acts as de novo 5mC transferases. DNMT protein levels and activities were both 
found to be elevated in prostate cancer cells and tissues compared to normal controls (Gravina, 
Ranieri, Muzi et al., 2013,Patra, Patra, Zhao et al., 2002). De novo 5mC by DNMT3a and 
DNMT3b was reported to be remarkably increased in aggressive PCa cell lines whereas DNMT1 
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activity appears to be more related to the early stages of malignancy (Gravina et al., 2013). 
TET1 promoter hypermethylation has recently been reported in prostate cancer as well as in 
multiple other cancers (Chim et al., 2010,Cimmino et al., 2015,Kim, Pierscianek, Mittelbronn et 
al., 2011,Li, Li, Mao et al., 2016). Surprisingly, more detailed investigation of the TET1 promoter 
region has shown that the observed hypermethylation in prostate cancer is not correlated with its 
expression (Figure 3). In contrast, reduced TET1 expression levels were found to be correlated 
with hypermethylation throughout the TET1 promoter region in breast cancer.  
 
 
Figure 3: Methylation profile of TET1 promoter. [A] Depicting methylation profiles for (equally-spaced) 
probes in the promoter and first intron of TET1 for TCGA prostate samples (cg12630147 is 
highlighted)(Cancer Genome Atlas Research, 2015). The pattern is the same as [C] seen in Breast 
samples from TCGA. [D] Aggregated public data show that the difference in methylation seen in TCGA 
between Tumor and Normal tissue of the first-intron regulatory region of TET1 is part of a larger trend. 
Depicted are average levels (Beta values) for Blood (from PCa patients), ‘Normal' prostate tissue (from 
non-PCa patients), ‘Benign’ apparently normal tissue (from PCa patients), Hyperplastic tissue, PIN, PCa 
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and Metastasis. For a number of probes in the first intron, including cg12630147 (highlighted), there is a 
general trend of greater methylation with malignancy. This figure is based on data retrieved from: (Aryee, 
Liu, Engelmann et al., 2013,Brocks et al., 2014,Cancer Genome Atlas Research, 2015,Massie et al., 
2015,Naeem, Wong, Chatterton et al., 2014,Paziewska, Dabrowska, Goryca et al., 2014) [B] The 
correlation profiles of each methylation probe and TET1 gene expression from TCGA are presented, 
showing that methylation of the first intron does not regulate TET1 expression in prostate cancer as it 
does in breast. [E] The patterns of association between methylation and expression are highlighted for 
probe cg12630147. TCGA data were obtained from the Wanderer tool.  
 
Recent studies have proposed an interaction between the androgen receptor (AR) and TET 
regulation. Dhiman and colleagues reported a role for the AR in the regulation of DNA 
methylation patterns in gene regulatory regions (Dhiman, Attwood, Campbell et al., 2015). 
MicroRNAs such as the miR-29 family are induced upon androgen stimulation and repress TET2 
in a high risk prostate cancer model (Takayama, Misawa, Suzuki et al., 2015) (Figure 4). 
Moreover, TET2 transcription can be directly repressed by binding of activated AR to the distal 
enhancer region of TET2 (Takayama et al., 2015). Furthermore, the AR itself can also be 
silenced by DNA methylation in a subset of androgen-deprivation treated prostate cancers, 
promoting the development of the disease towards an androgen-independent phenotype 
(Jarrard, Kinoshita, Shi et al., 1998,Kinoshita, Shi, Sandefur et al., 2000,Yamanaka, Watanabe, 
Yamada et al., 2003). Therefore, it is possible to predict a model whereby a balanced network of 
links between AR signaling and TET activity are disrupted at different stages of tumorigenesis to 
drive first epigenetic changes and subsequently evolution of resistance to therapy.  
 
Hypoxia has been recognized as an important factor in promoting tumor malignancy (Harris, 
2002,Ljungkvist, Bussink, Kaanders et al., 2006,Semenza, 1999). Preclinical data have shown 
that hypoxia can induce the selection of aggressive cancer which is characterized by reduced 
sensitivity to apoptosis and DNA repair and an increased angiogenesis, proliferation and 
metastatic potential (Subarsky and Hill, 2003). Hypoxic primary tumors also form a greater risk 
of developing progressive disease (Milosevic, Fyles, Hedley et al., 2004), and prognostic 
signatures for poor outcome in prostate cancer include tumor hypoxia (Lalonde, Ishkanian, 
Sykes et al., 2014). Increased angiogenesis preceded by hypoxia signaling has been reported in 
PCa as well (Milosevic, Chung, Parker et al., 2007). Several groups have shown that TET is 
directly regulated by HIF-1a through binding near its promoter region (Mariani et al., 
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2014,Thienpont et al., 2016,Wu et al., 2015) in addition to the direct effects of oxygen availability 
on TET enzyme activity. In PCa, there might also be an additional role for androgens in hypoxia 
control through the transcriptional regulation of angiogenesis factors, providing another potential 
link between PCa biology and TET regulation (Boddy, Fox, Han et al., 2005,Fernandez, Reece, 
Ley et al., 2015,Horii, Suzuki, Kondo et al., 2007,Woodward, Wachsberger, Burd et al., 2005). 
 
6.3 TET protein activity in prostate cancer 
In addition to the transcriptional regulation of TET genes, the activity and stability of these 
enzymes is regulated at the protein level (as outlined in section 4.2). In PCa, androgen signaling 
regulates both the expression of TET genes and the recruitment of TET proteins to methylated 
DNA. In prostate epithelial cell lines, stimulation of the AR has been reported to induce dynamic 
patterns of 5mC in the vicinity of the androgen responsive elements (AREs) at AR target genes 
resulting in selective access of regulatory factors to these regions (Dhiman et al., 2015). 
Strikingly, TET1 and TDG seem to be co-recruited to these regions upon AR stimulation, 
indicating an important role for local demethylation in the transcriptional regulation of AR target 
genes. However, these findings requires further validation and investigation of whether the AR 
itself is responsible for the recruitment of TET and TDG to the target genes. A recent publication 
even shows that TET2 and the AR can form a complex to regulate the expression of androgen-
responsive genes (Nickerson, Das, Im et al., 2016).  
Furthermore, there is a clear link between metabolic alterations in PCa and TET protein activity. 
As oxygen and 2-OG dependent enzymes, TET proteins are acutely regulated by the 
microenvironment and cellular metabolism. For example prostate tumors frequently present with 
regions of hypoxia, and a recent study showed that TET activity is reduced in hypoxic conditions 
which was associated with hypermethylation of many gene promoters (Thienpont et al., 2016). 
This provides one explanation for the early and recurrent 5mC alterations observed in PCa 
tumors.  
Mutations in TCA enzymes IDH1 (cytosolic) and IDH2 (mitochondrial) are frequently identified in 
acute myeloid leukemia, glioma, chondrosarcoma, enchondroma and thyroid cancer patients, 
and have also been found in 1% of patients with localized PCa (Chan, Milosevic and Bristow, 
2007,Kang, Kim, Oh et al., 2009). A recent TCGA study defined PCa cases with IDH1 mutations 
as a separate molecular subclass (Cancer Genome Atlas Research, 2015). Importantly, mutant 
IDH enzymes are often not catalytically inactive, but have an altered catalytic activity resulting in 
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the conversion of isocitrate to the oncometabolite 2-hydroxyglutarate (2-HG) instead of 2-OG 
(Amary, Bacsi, Maggiani et al., 2011,Dang, White, Gross et al., 2009,Hemerly, Bastos and 
Cerutti, 2010,Mardis, Ding, Dooling et al., 2009,Murugan, Bojdani and Xing, 2010,Pansuriya, 
van Eijk, d'Adamo et al., 2011,Yang, Ye, Guan et al., 2012). Accumulation of this alternative 
metabolite prevents catalytic activity of TET enzymes by competing with 2-OG for binding in the 
catalytic site of 2-OG-dependent dioxygenases (Xu et al., 2011). Furthermore, a link was also 
proposed between the IDH and hypoxia. 2-OG is required for proper function of 
prolylhydroxylases (PHD) which are responsible for hydroxylation and promotion of HIF1α 
degradation. When conversion of isocitrate is deflected towards the formation of 2-HG, PHD 
won’t be able to degrade HIF1α and favoring angiogenesis (Zhao, Lin, Xu et al., 2009). Given 
the spatial heterogeneity of hypoxia in PCa (Boutros, Fraser, Harding et al., 2015) and its 
potential to apply selective pressure, foci with mutations in IDH1 might be favored in this 
environment. This raises the question whether the 1% of PCa samples defined in the IDH1 
subclass of the TCGA classification are representative or if there might be more cases wherein 
IDH1 mutations are not sampled.  
High levels of zinc in the prostate inhibit the activity of the TCA enzyme aconitase (ACO) 
(Costello, Liu, Franklin et al., 1997) and some reports have shown that intracellular zinc 
concentrations fall during PCa development (Desouki, Geradts, Milon et al., 2007,Singh, 
Desouki, Franklin et al., 2006). The resulting alterations in the TCA cycle upstream of 2-OG 
production may impact TET activity as well as the 5hmC dynamics during PCa development. 
Future studies will be needed to assess the functional consequences of this prostate-specific 
phenotype at different stages of prostate malignancy.    
Together, there are many mechanisms acting at different levels to regulate TET activity. In this 
section we discussed the majority of these mechanisms applicable for prostate cancer (Figure 
4). Future and ongoing research will help to identify new mechanisms and elucidate the role of 
pathways already reported in PCa or other cellular contexts.  
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Figure 4: Overview of the important mechanisms influencing TET transcriptional activity and 
activity and stability in prostate cancer. Many different pathways are altered during PCa development 
and/or progression. TET activity and stability is dependent on mutations in the TET encoding genes, 
transcription, androgen regulation and metabolic state such as hypoxia and glucose metabolism. On the 
other hand, TET transcriptional activity can be regulated by methylation of CpG islands in its regulatory 
regions, TET mutations, androgen signaling partly via miRNAs, hypoxia, products of the TCA cycle and 
altered transcription factor levels and activities such as OCT4 and HMGA2.  
 
7 Methods for epigenetic profiling of prostate samples 
In order to better understand the spatial and temporal regulation of TET proteins numerous 
methods have been developed to detect and quantify the 5hmC content of genomic DNA.  
These methods leverage specific chemical conversions, enzymatic labeling, affinity enrichment 
or direct detection (Table 1).  Each 5hmC analysis method has specific advantages and 
limitations; the appropriate choice of method for a given application depends on factors 
including: the required genomic coverage; the amount of input material available; the number of 
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samples to be analyzed; and the optimal sequence resolution (Skvortsova, Zotenko, Luu et al., 
2017). Careful consideration should be given to the balance between genomic resolution and 
analytical complexity. Methods that provide a quantitative signal across a genomic locus can 
allow a high-throughput analysis of differences between tumor and normal, or groups of tumors 
with different clinical features. In contrast, methods that allow single base resolution are more 
costly and have a much higher analytical burden, but can identify differences (and patterns of 
differences) that would be missed using locus-averaging methods. 
7.1 Chemical conversion of 5hmC 
Methods using sodium bisulfite conversion (BS) may be considered the current ‘gold standard’ 
for the analysis of cytosine modifications (Frommer, McDonald, Millar et al., 1992). BS treatment 
results in the deamination of unmethylated cytosines to uracil (that is subsequently converted to 
thymine), whereas both 5mC and 5hmC are protected from BS-conversion (and subsequently 
read out as cytosines; Table 1).  Oxidative bisulfite conversion (oxBS) is specific for 5mC alone 
and therefore the subtraction of oxBS from BS signals allows the specific identification of 5hmC-
modified sites (Booth, Branco, Ficz et al., 2012).  This subtractive analysis can provide digital 
genome-wide base-pair resolution analysis of both 5mC and 5hmC, albeit at significant financial 
and computational cost. The original methods for BS-seq and oxBS-seq require large amounts 
of input material (micrograms of genomic DNA) (Booth et al., 2012,Frommer et al., 1992,Lister, 
O'Malley, Tonti-Filippini et al., 2008). However, optimized protocols have been developed that 
allow lower amounts of starting material (~100ng) (Miura, Enomoto, Dairiki et al., 2012), opening 
the way for BS/oxBS analysis of precious clinical samples. It is currently not practical to use 
genome-wide sequencing implementations of these methods in studies with large clinical sample 
collections due to prohibitive costs and the absence of standardized analysis pipelines for 
quantitative differential analysis. Array hybridization platforms for BS analysis have been widely 
used in several large-scale studies (e.g. TCGA and ICGC) including several prostate cancer 
cohort studies (Brocks et al., 2014,Cancer Genome Atlas Research, 2015). However, the most 
popular platform (Illumina 450k array) is no longer in production and the cost of dual analysis 
(BS/oxBS) to differentiate 5mC and 5hmC marked loci on newer array platforms is similar to 
sequencing based approaches. Where prior knowledge of informative loci exists, as is the case 
for prostate cancer (Cancer Genome Atlas Research, 2015,Spans et al., 2016), a targeted 
BS/oxBS-sequencing approach is both practical and affordable for use in large cohort studies 
(BlueprintConsortium, 2016). 
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7.2 Affinity enrichment of 5hmC 
In contrast, affinity enrichment methods offer a practical high-throughput alternative to map 
genomic loci marked with 5mC or 5hmC (Table 1). These approaches enrich (or ‘pull-down’) 
DNA fragments containing the modification of interest using specific antibodies (MeDIP/hMeDIP)  
(Ficz et al., 2011,Pomraning, Smith and Freitag, 2009,Weber, Davies, Wittig et al., 2005) or 
base-modification binding proteins (e.g. MDB-seq/JBP1-seq) (Robertson, Dahl, Vagbo et al., 
2011,Serre, Lee and Ting, 2010). The relative enrichment at specific genomic loci provides a 
quantitative read-out of cytosine modifications at that locus and allows comparative analysis 
between conditions or cell types. For example, hMeDIP has been applied to clinical prostate 
cancer samples and has identified extensive heterogeneity in 5hmC profiles between tumor and 
normal tissue (Spans et al., 2016). Lower costs and less complex downstream analysis make 
affinity enrichment methods a practical option for large-scale studies that aim to identify or 
monitor differences between cell types or treatment conditions (Uribe-Lewis, Stark, Carroll et al., 
2015,Yegnasubramanian, Wu, Haffner et al., 2011). The resolution of affinity enrichment 
methods is limited by the input DNA fragment length (e.g. 100-400bp) and in most methods the 
output provides an average signal across a locus, meaning that focal and low-level differences 
may be missed in such analyses. Most affinity-based methods also require relatively large 
amounts of input material (micrograms of DNA) to analyze both 5mC and 5hmC genome-wide. 
7.3 Enzymatic labeling of 5hmC 
Several 5hmC analysis methods have employed enzymatic covalent tagging of 5hmC bases 
using T4 bacteriophage β-glucosyltransferase (β-GT) (Bhattacharyya et al., 2013,Pastor, Pape, 
Huang et al., 2011,Petterson, Chung, Tan et al., 2014,Song, Szulwach, Fu et al., 2011,Yu, Hon, 
Szulwach et al., 2012). The β-GT enzyme labels 5hmC residues with glucose molecules, either 
protecting these residues from chemical conversion (TAB-seq) (Yu et al., 2012) or restriction 
enzyme digestion (HELP-GT, RRHP) (Bhattacharyya et al., 2013,Petterson et al., 2014).  
Alternatively, β-GT can incorporate azide-glucose moieties at 5hmC positions, allowing 
subsequent tagging with N-hydroxysuccimide-esters to incorporate either biotin for enrichment 
methods (hm-Seal) (Song et al., 2011) or fluorophores for direct single molecule quantification 
(Song, Diao, Brunger et al., 2016).  Modifications of these methods allow analysis from 
nanograms of input DNA (nano-hmC-Seal) (Han, Lu, Shih et al., 2016), allowing 5hmC analysis 
in small samples (~1000 cells).  Most implementations of β-GT tagging of 5hmC result in 
quantitative signals at a locus-wide level and therefore may miss focal and low-level differences 
between samples similar to affinity enrichment methods.  
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7.4 Direct detection of 5hmC 
Direct analysis of 5hmC would circumvent many of the limitations inherent to the methods 
outlined above: inaccuracies from chemical conversion or enzymatic labeling efficiencies; 
amplification bias and lack of complete genomic coverage; the analytical burden of indirect and 
subtractive, relative analysis. Single molecule sequencing platforms (e.g. Nanopore and PacBio) 
offer the capability for direct detection of modified bases in native DNA molecules (Laszlo, 
Derrington, Brinkerhoff et al., 2013,Schreiber, Wescoe, Abu-Shumays et al., 2013,Wanunu, 
Cohen-Karni, Johnson et al., 2011). The long read lengths of these platforms also allow analysis 
of genomic regions that are inaccessible to short read and array-based platforms. For example, 
a recent study using single molecule real-time sequencing mapped base modifications within 
specific LINE repeats in the human genome (Suzuki, Korlach, Turner et al., 2016).  Alternative 
single molecule approaches are also being developed, including β-GT fluorophore labeling of 
single native DNA molecules and direct detection and quantification (Song et al., 2016). Current 
implementations of these single molecule technologies have limited throughput (e.g. number of 
reads per sequencing run), making genome-wide analysis difficult and also require large 
amounts of starting material. In addition, the analysis methods for these newer technologies are 
not standardized and continuing platform improvements make standardization unlikely in the 
short-term. However, these methods are constantly improving and with increased throughput are 
likely to offer the deepest insights into DNA base modifications (including 5hmC) in the future. A 
particular advantage with respect to prostate cancer analysis is the fast sample-to-data 
turnaround times, opening the possibility of real-time analysis of patient samples in the clinic to 
improve diagnostic workflows, prognostication or treatment selection. 
 
 Method Name Description Advantages a Disadvantages b References 
7.
1 
Ch
em
ica
l c
o
n
ve
rs
io
n
 
BS and OxBS-
sequencing 
Bisulfite conversion 
(5mC + 5hmC) minus 
Ox-bisulfite conversion 
(5mC)  
Digital signal, base-
pair resolution 
DNA fragmentation, 
input >1µg, BS + OxBS 
analysis for subtract. 
analysis 
(Booth et al., 
2012,Frommer et 
al., 1992) 
Tn5mC-seq Tagmentation library 
prep, followed by BS or 
OxBS 
Efficient library prep, 
low input (10ng) 
Requires high quality 
input DNA, BS/oxBS 
after tagmentation 
reduces complexity  
(Adey and 
Shendure, 
2012,Wang, Gu, 
Adey et al., 2013) 
PBAT  Bisulfite treatment, 
followed by library prep 
100ng DNA for 
WGBS, base pair 
resolution 
Would require BS and 
OxBS analysis for 
subtractive analysis 
(Miura et al., 2012) 
 
Af
fin
ity
 
e
n
ric
hm
CMS-pulldown BS conversion of 5hmC 
to CMS and anti-CMS 
antibody pull-down  
Quantitative,  
high-throughput, 
lower analytical 
burden 
BS conversion and 
antibody specificity/ 
efficiency, locus avg. 
(Pastor et al., 2011) 
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hMeDIP-seq 5hmC-specific  
antibody pull-down 
Direct 5hmC test, 
quantitative, high-
throughput, lower 
analytical burden 
Locus wide signal, 
resolution limited by 
fragment length, Ab- 
specificity (1µg input) 
(Ficz et al., 
2011,Williams et al., 
2011) 
 
JBP1-pulldown T4 β–GT tagging and 
JBP1 pull-down 
Reagents generated 
in-house, HTP 
method 
Fragment resolution, 
high input (1-100µg 
DNA) 
(Robertson et al., 
2011,Robertson, 
Dahl, Ougland et 
al., 2012) 
7.
3 
En
zy
m
e
 
co
n
ve
rs
io
n
 
GLIB, hmC-Seal,  
nano-hmC-Seal 
T4 β-GT biotin-tagging of 
5hmC 
Quantitative, low 
input (ng DNA), HTP 
Resolution limited by 
fragment length, locus 
average signal 
(Han et al., 
2016,Pastor et al., 
2011,Song et al., 
2011) 
TAB-seq  T4 β-GT 5hmC 
protection, Tet 5mC 
oxidation, BS convert. 
Base pair resolution, 
5hmC readout  (not 
BS /   oxBS 
subtractive) 
Dependent on 
enzymatic and BS 
conversion efficiency 
(Yu et al., 2012) 
MspI/HpaII digest 
+/- β-GT variants: 
HELP-GT, RRHP, 
HMST 
HpaII / MspI digest  
+/- β-GT protection of 
5hmC 
Up to base-pair 
resolution, sensitive, 
100ng-1µg input 
Single CpG/fragment, 
GC-rich loci, relative 
analysis (5hmC/5mC) 
(Bhattacharyya et 
al., 2013,Khare, 
Pai, Koncevicius et 
al., 2012,Petterson 
et al., 2014) 
Aba-seq or Pvu-
seal-seq 
5hmC-specific restriction 
digest with β-GT tagging 
and biotin pulldown 
Up to base pair 
resolution, high 
sensitivity 
Single CpG analyzed 
per fragment, digest 
and tagging efficiency 
(Sun, Dai, Borgaro 
et al., 2015) 
Thiol, selenol or 
aldehyde enzyme 
tagging 
M.HhaI/M.SssI tag with 
R-SH/R-SeH donor, then 
NHS-ester labeling  
Direct 5hmC labeling, 
flexible tagging 
workflow 
Not extensively 
validated, ~20% 
recovery and ~1% FP  
(Liutkeviciute, 
Lukinavicius, 
Masevicius et al., 
2009,Liutkeviciute, 
Kriukiene, Grigaityte 
et al., 2011) 
7.
4 
Si
n
gl
e
 
m
o
le
cu
le
 
a
n
a
lys
is 
Direct single 
molecule 
sequencing 
Direct 5hmC detection in 
single molecule SMRT or 
nanopore sequencing 
Direct detection, 
digital readout, long 
reads, low consensus 
error, rapid output 
High input DNA, no 
standardized analysis, 
low reads per run for 
WGS analysis 
(Flusberg, Webster, 
Lee et al., 
2010,Laszlo et al., 
2013,Schreiber et 
al., 2013,Wanunu et 
al., 2011) 
Tagged single 
molecule 
sequencing 
T4 β-GT biotin tag and 
SMRT-seq or nanopore 
seq 
Improved signal with 
bulky Glc. 
modification 
Dependent on tagging 
efficiency 
(Song, Clark, Lu et 
al., 2011,Zahid, 
Zhao, He et al., 
2016)  
BS and Ox-BS 
single molecule 
sequencing 
Bisulfite conversion and 
SMRT-seq  
Longer read analysis: 
captures regions not 
possible by short-
reads 
Ox-BS conversion 
efficiency, DNA 
fragmentation  
(Yang, Sebra, 
Pullman et al., 
2015) 
 
Thiol labeling (BS 
mediated) 
Thiolation of 5hmC in 
ssDNA with nanopore 
seq 
Improved detection of 
5hmC 
Efficiency, specificity  
and throughput not well 
characterized 
(Lu and He, 2013) 
Table 1: Summary of selected published methods for the analysis of 5hmC. Subset: BS-conversion; 
affinity enrichment; enzymatic tagging; direct analysis. a Base-pair resolution methods allow the 
assessment of individual cytosine residues at each locus analyzed. b Locus average methods provide a 
global view of 5mC and 5hmC at a given locus (in most cases the resolution is defined by DNA fragment 
lengths in the input material).  
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8 Conclusions 
The importance of TET enzymes and 5hmC in development and disease is clear, as are the 
multiple levels of regulation of these important epigenetic regulators.  By contrast, the role of 
these proteins in PCa is only beginning to be understood, but the combination of insights from 
studies in other systems and high-throughput analysis methods offer great potential for future 
studies. Over the coming years we will no doubt learn more about the role of TET and 5hmC in 
PCa biology, and the potential for TET proteins and their targets to act as disease markers and 
therapeutic targets to improve patient outcomes. 
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